Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK3277511A Vaccine in Adults
NCT02547974Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2015
- Primary completion
- Mar 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3277511A in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Any Solicited Local Adverse Events, Number of Subjects With Any Solicited General Adverse Events and 4 more. Started Aug 2015; status: completed.
02
Drugs
GSK3277511A
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02547974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02547974.